Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Decreases By 22.0%

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,450,000 shares, a drop of 22.0% from the April 15th total of 1,860,000 shares. Approximately 7.8% of the company's stock are sold short. Based on an average trading volume of 196,500 shares, the short-interest ratio is currently 7.4 days.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SYRS. Acadian Asset Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at about $91,000. Vanguard Group Inc. increased its holdings in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock valued at $4,965,000 after buying an additional 163,234 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Syros Pharmaceuticals by 576.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company's stock valued at $909,000 after buying an additional 144,869 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Syros Pharmaceuticals during the 4th quarter worth approximately $2,799,000. Finally, Flagship Pioneering Inc. boosted its position in shares of Syros Pharmaceuticals by 30.2% during the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company's stock worth $10,079,000 after acquiring an additional 300,000 shares in the last quarter. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Stock Performance

NASDAQ SYRS traded down $0.04 on Friday, hitting $4.97. 139,504 shares of the stock were exchanged, compared to its average volume of 143,222. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.95 and a quick ratio of 3.95. The company has a market capitalization of $132.85 million, a PE ratio of -0.86 and a beta of 1.75. The business's fifty day moving average is $5.62 and its 200 day moving average is $5.50. Syros Pharmaceuticals has a 52 week low of $2.09 and a 52 week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.04. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $2.40 million. Research analysts anticipate that Syros Pharmaceuticals will post -3.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SYRS has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, April 1st. Piper Sandler restated an "overweight" rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, StockNews.com downgraded Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, April 17th.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.